Subscribe
Sign in
Subscribe
Sign in
GlobalData
GlobalData

Pharma

Three BiTEs set to disrupt relapsed/recurrent multiple myeloma space with $9 billion sales by 2030, says GlobalData

Recent developments in the field of bispecific T-cell engagers (BiTEs) have led to the approval of three therapies for relapsed/recurrent multiple myeloma (RRMM): Elrexfio (elranatamab) developed by Pfizer, Tecvayli (teclistamab) and Talvey (talquetamab) developed by Johnson & Johnson. Clinical data of the three have been surprising, surpassing previously anticipated response rates. With an ever-growing number […]
Read more

Cell and gene manufacturers benefit from surge in FDA drug approvals, says GlobalData

2023 marked a significant upsurge in FDA approvals, particularly for groundbreaking treatments such as cell and gene therapies. This surge highlights not just advancements in medical technology but also provides substantial opportunities for manufacturers specializing in these cutting-edge therapies. Looking ahead to 2024-25, the pharmaceutical industry braces for challenges marked by increasing drug approvals, innovative […]
Read more

ESCMID Global 2024 echoes multidisciplinary calls to action, finds GlobalData

Working towards a multidisciplinary approach to navigate the future of infectious diseases has been a key theme at the 34th European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global* 2024 congress. Key concerns such as climate change and antimicrobial resistance (AMR) were underscored, emphasizing the need for collaborative efforts beyond traditional medical realms. Initiatives […]
Read more

APAC leads in asthma clinical trials between 2019-2023, says GlobalData

The Asia-Pacific (APAC) region is leading in clinical trials in Asthma between 2019-2023, with China, India, and South Korea among the top countries in this space, according to GlobalData, a leading data and analytics company. According to GlobalData’s Clinical Trials Database, during 2019-23, 51.8% of asthma trials were initiated in the APAC region. China emerged […]
Read more

Chinese companies lead ADC development pipeline, reveals GlobalData

Antibody drug conjugates (ADCs) are a rapidly growing therapeutic class, and Chinese companies are leading the ADC trend, accounting for half of the top 10 developers as they seek to capitalize on potential returns. The significant level of Chinese innovation and presence within the new cancer therapy space underlies the country’s emergence as a key […]
Read more

Samsung Biologics set to thrive if BIOSECURE bill passes in US, says GlobalData

The biopharmaceutical industry has been buzzing over the US government’s unveiling of the BIOSECURE bill. Introduced in the House of Representatives in January 2024, the bill mainly aims to restrict federal government funding and/or partnerships with a few Chinese companies deemed a threat to national security. Samsung Biologics, a South Korean biopharmaceutical contract development, and […]
Read more

Biohaven’s Taldefgrobep alfa could target broad SMA patient population, says GlobalData

At the American Academy of Neurology (AAN) 2024 Annual Meeting, Biohaven presented its Phase III RESILIENT (NCT05337553) trial design, which investigates the efficacy and safety of taldefgrobep alfa in patients with spinal muscular atrophy (SMA). Taldefgrobep alfa is a myostatin inhibitor in development as an adjunctive therapy alongside marketed therapies to offer symptomatic relief to […]
Read more

Oligonucleotides and mRNA vaccines dominate in strategic alliances for RNA-therapies in major APAC countries, says GlobalData

RNA-based therapies have already proven and will continue to play an integral role in the development of novel therapeutic agents for diseases in the future. Against this backdrop, biopharmaceutical companies based in the major Asia-Pacific (APAC) countries (Australia, China, Japan, and South Korea) entered into significant partnerships to develop RNA-based therapies in the last five […]
Read more

Radius Pharmaceuticals’ Tymlos will have to face highly competitive osteoporosis market despite positive results, says GlobalData

Radius Pharmaceuticals unveiled real-world evidence at the recently held World Congress on Osteoporosis, Osteoarthritis, and Musculoskeletal Diseases, demonstrating increased efficacy of Tymlos (abaloparatide) therapy in reducing hip and non-vertebral fractures compared to teriparatide in women aged 50 years and older. Despite positive results, Tymlos will have to face a highly competitive osteoporosis market, according to […]
Read more

APPLAUSE-IgAN trial interim analysis highlights Novartis’ potential to differentiate in IgAN space, says GlobalData

At this year’s World Congress of Nephrology, positive results were presented from Novartis’s pre-specified interim analysis of the Phase III APPLAUSE-IgAN clinical trial. According to the analysis, the use of Fabhalta (iptacopan) was shown to reduce proteinuria in patients with immunoglobulin A (IgA) nephropathy (IgAN) compared to placebo. The drug potentially fills an unmet need […]
Read more

AstraZeneca’s Lynparza to dominate PARP inhibitors market with $4 billion in sales by 2027, says GlobalData

In 2014, the FDA approved the first (adenosine diphosphate-ribose) polymerase (PARP) inhibitor AstraZeneca/Merck’s Lynparza (olaparib) for use in breast cancer gene (BRCA)-mutated metastatic ovarian cancer patients who have received three or more prior lines of chemotherapy. Since then, the PARP inhibitors market has made significant strides, but Lynparza maintains its dominance with projected global sales […]
Read more

Sintilimab and fruquintinib combination to face stiff competition in endometrial cancer market in China, says GlobalData

Innovent Biologics Inc and HUTCHMED (China) have recently announced the acceptance of new drug application (NDA) for fruquintinib (Elunate) in combination with sintilimab (Tyvyt) for the treatment of advanced endometrial cancer with pMMR or non-MSI-H tumors that have failed prior systemic therapy but are not candidates for curative surgery or radiation with priority review status […]
Read more

Hospitalized incident cases of MRSA to reach 791,000 in 7MM in 2033, forecasts GlobalData

The burden of hospitalized incident cases of methicillin-resistant Staphylococcus aureus (MRSA) is forecast to increase at an annual growth rate (AGR) of 1.08% from around 714,000 cases in 2023 to 791,000 cases in 2033 in the seven major markets (7MM*), according to GlobalData, a leading data and analytics company. GlobalData’s latest report, ‘Methicillin Resistant Staphylococcus […]
Read more

ACC 24: Empagliflozin remains competitive therapy in HF market despite EMPACT-MI trial outcome, says GlobalData

At the American College of Cardiology’s (ACC) 73rd Annual Scientific Session, the results of Eli Lilly and Boehringer Ingelheim’s Phase III EMPACT-MI trial, which examined patients treated with sodium-glucose co-transporter-2 inhibitor (SGLT-2I) empagliflozin (Jardiance) following a heart attack, were reported. However, the treatment with empagliflozin did not impact the study’s primary endpoint of a combination […]
Read more

Alzheon’s oral anti-amyloid drug has potential to be first oral Aβ-targeting therapy approved in US and EU, says GlobalData

Given the complex pathophysiology of Alzheimer’s disease (AD), developing disease modifying therapies (DMTs) that target different aspects of AD pathology is critical. American clinical-stage biopharmaceutical company Alzheon has recently presented promising interim results from its Phase II Biomarker Trial (NCT04693520) of its oral, brain-penetrant, amyloid-oligomer inhibitor ALZ-801 (valiltramiprosate) at the American Academy of Neurology (AAN) […]
Read more

Roche’s PRX-002 shows promise in slowing Parkinson’s disease motor progression, says GlobalData

There are currently no marketed disease-modifying therapies (DMTs) for Parkinson’s disease (PD). At the American Academy of Neurology (AAN) 2024 annual meeting, Roche presented positive four-year results from a six-year open-label extension of their Phase II “PASADENA” trial evaluating the efficacy of PRX-002 (prasinezumab), a potentially PD modifying monoclonal antibody. These latest results strengthen the […]
Read more

ACC 24: Novo Nordisk’s Semaglutide will continue to retain leading position in cardiovascular market, says GlobalData

At the American College of Cardiology’s 73rd Annual Scientific Session, a study from the Gardy Health system in Atlanta, Georgia, US was presented investigating the rates of heart failure hospitalizations (HFH) in heart failure with preserved ejection fraction (HFpEF) patients and diabetes patients on semaglutide. Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA) developed by […]
Read more

Elahere and Keytruda pave way to ADC and ICI strategies in endometrial cancer, says GlobalData

At the recently held 2024 American Association for Cancer Research (AACR) Annual Meeting, positive Phase II trial results of the combination of Immunogen’s antibody-drug conjugate (ADC) Elahere and Merck & Co’s immune checkpoint inhibitor (ICI) Keytruda in the treatment of folate receptor-alpha (FR-α) positive recurrent microsatellite stable / mismatch repair proficient serous endometrial cancer were […]
Read more
1 … 21 22 23 24 25 … 110